This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering

Designing novel protein therapeutics and identifying appropriate targets - WHITEPAPER

Since the introduction around 30 years ago of the first recombinant protein therapeutic (human insulin), protein therapies have increased dramatically in number and frequency of usage. The benefits of proteins over small-molecule drugs rooted their extensive influence in the pharmaceutical market and there are currently more than 130 different proteins or peptides approved for clinical use by the FDA, and many more are in development.

This whitepaper explores designing novel protein therapeutics and identifying appropriate targets, including:

  • The challenges with creating novel protein therapeutics in the R&D stage and how can they be overcome

  • Factors to consider when identifying targets and how does it affect protein design

  • Best ways to identify appropriate targets

  • Understanding Bioavailability

To download simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content. 

Have any questions about the report or interested in sponsoring a future whitepaper? Email

Log in or Create an Informa Connect Account to Access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.